skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Derrick Gingery
Senior Writer
Pink Sheet



New Drug, Generic Drug, and Biosimilar Regulatory Policy


Pink Sheet




Pink Sheet’s Derrick Gingery has spent more than 11 years covering the prescription drug industry and has been a professional journalist for more than 23 years. During his time at the Pink Sheet, he has covered three user fee renewal cycles, FDA policy, and relevant legislation on Capitol Hill, as well as new and generic drug approvals and their impact on the broader landscape. He also hosts the Pink Sheet’s regulatory podcast, where he and his colleagues discuss the impact of FDA and industry news.

US FDA User Fee Program

The US FDA's prescription drug, generic drug, and biosimilar user fee programs are expected to generate nearly $1.8bn in revenue in FY 2022 to help pay for marketing application reviews, manufacturing facility inspectins, and policy development. We have been closely reporting on the program renewal process, which takes place every five years, and is where industry and FDA representatives determine fee calculations, update application review timelines, and outline other policy changes with wide-ranging impact on developing and marketing drugs in the US. The agreement will then be turned into legislation that Congress will use to make additional changes at the agency.

Decode the complex worlds of compliance, legislation, policy, and industry developments with actionable news and analysis from the industry experts at Pink Sheet..

Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments.

Register for your free trial today to find out what our editors and journalists are reporting on now.


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: